297 related articles for article (PubMed ID: 12503774)
1. Pharmacokinetics and bioavailability of four modified-release ursodeoxycholic acid preparations for once-a-day administration.
Simoni P; Sabatini L; Baraldini M; Mirasoli M; Roda A; Roda E
Int J Clin Pharmacol Res; 2002; 22(2):37-45. PubMed ID: 12503774
[TBL] [Abstract][Full Text] [Related]
2. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
Dulac O; Alvarez JC
Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of ursodeoxycholic acid bioavailability from immediate- and sustained-release preparations using gas chromatography-mass spectrometry and high-performance liquid chromatography.
Scalia S; Scagliarini R; Pazzi P
Arzneimittelforschung; 2000 Feb; 50(2):129-34. PubMed ID: 10719615
[TBL] [Abstract][Full Text] [Related]
4. Bioavailability of a controlled release formulation of ursodeoxycholic acid in man.
Alvisi V; Gasparetto A; Dentale A; Heras H; Felletti-Spadazzi A; D'Ambrosi A
Drugs Exp Clin Res; 1996; 22(1):29-33. PubMed ID: 8839635
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
Wangemann M; Retzow A; Vens-Cappell B
Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
[TBL] [Abstract][Full Text] [Related]
7. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
[TBL] [Abstract][Full Text] [Related]
8. Results of a phase I multiple-dose clinical study of ursodeoxycholic Acid.
Hess LM; Krutzsch MF; Guillen J; Chow HH; Einspahr J; Batta AK; Salen G; Reid ME; Earnest DL; Alberts DS
Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):861-7. PubMed ID: 15159320
[TBL] [Abstract][Full Text] [Related]
9. [Comparative bioavailability and pharmacokinetics of Dolotren retard and Dolotren].
Honorato J; Montes B; Suárez J; Lucero ML; Valiente R
Rev Med Univ Navarra; 1992; 37(1):7-16. PubMed ID: 1626168
[TBL] [Abstract][Full Text] [Related]
10. Bioavailability of four ursodeoxycholic acid preparations.
Williams CN; Al-Knawy B; Blanchard W
Aliment Pharmacol Ther; 2000 Sep; 14(9):1133-9. PubMed ID: 10971229
[TBL] [Abstract][Full Text] [Related]
11. Bioavailability and pharmacokinetic properties of 2 sustained-release formulations of diclofenac sodium, Voltaren vs inflaban: effect of food on inflaban bioavailability.
Zmeili S; Hasan M; Najib N; Sallam E; Deleq S; Shubair M
Int J Clin Pharmacol Ther; 1996 Dec; 34(12):564-70. PubMed ID: 8996854
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of oral morphine sulfate in dogs: a comparison of sustained release and conventional formulations.
Dohoo SE; Tasker RA
Can J Vet Res; 1997 Oct; 61(4):251-5. PubMed ID: 9342447
[TBL] [Abstract][Full Text] [Related]
13. [The pharmacokinetics and bioequivalence of acipimox sustained-release tablets after a single and multiple oral administration in healthy dogs].
Yang XG; Nie SF; Bai HJ; Zhang GJ; Pan WS
Yao Xue Xue Bao; 2005 May; 40(5):457-61. PubMed ID: 16220793
[TBL] [Abstract][Full Text] [Related]
14. Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.
Schuppan D; Molz KH; Staib AH; Rietbrock N
Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):223-7. PubMed ID: 7251238
[TBL] [Abstract][Full Text] [Related]
15. Bioequivalence of a new liquid formulation of ursodeoxycholic acid (Ursofalk suspension) and Ursofalk capsules measured by plasma pharmacokinetics and biliary enrichment.
Setchell KD; Galzigna L; O'Connell N; Brunetti G; Tauschel HD
Aliment Pharmacol Ther; 2005 Mar; 21(6):709-21. PubMed ID: 15771757
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of propranolol after single and multiple dosing with sustained release propranolol or propranolol CR (innopran XL) , a new chronotherapeutic formulation.
Sica D; Frishman WH; Manowitz N
Heart Dis; 2003; 5(3):176-81. PubMed ID: 12783630
[TBL] [Abstract][Full Text] [Related]
17. Different serum concentrations of steady-state valproic acid in two sustained-release formulations.
Yasui-Furukori N; Saito M; Nakagami T; Niioka T; Sato Y; Fujii A; Kaneko S
Psychiatry Clin Neurosci; 2007 Jun; 61(3):308-12. PubMed ID: 17472600
[TBL] [Abstract][Full Text] [Related]
18. In vivo performance of controlled release pellets of diltiazem HCl.
Nisarur-ur-Rahman ; K H Y; Jia Woei W
Pak J Pharm Sci; 2005 Apr; 18(2):44-8. PubMed ID: 16431398
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of controlled-release carbimazole tablets support once daily dosing in cats.
Frénais R; Burgaud S; Horspool LJ
J Vet Pharmacol Ther; 2008 Jun; 31(3):213-9. PubMed ID: 18471142
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 1. Single-dose administration].
Vens-Cappell B; Hilgenstock C; Gellert M; Kühle K; Reifferscheid I; Winckler P; Bührens KG
Arzneimittelforschung; 1993 Mar; 43(3):346-50. PubMed ID: 8489566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
